CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

2021 CADTH Symposium Call For Abstracts

May 18, 2021
CADTH is now accepting abstracts for workshops, panels, debates, breakfast sessions, oral presentations, and posters for the 2021 CADTH Symposium to be held online on November 2, 3, and 4. This year’s theme is Uncertain Times, Imperfect Evidence, and the Imperative to Act. Learn more about the theme. Abstracts must be submitted online at ...

New Report Highlights Recommendations to Reduce Low-Value Care Post-Pandemic

May 13, 2021
A new report from Choosing Wisely Canada (CWC) and CADTH looks ahead to post-pandemic health care in Canada. The report highlights consensus on evidence-based recommendations to reduce low-value care when health systems are ready to gradually resume the services and procedures that were put on hold due to COVID-19. The joint report, Using Healt...

Announcing the Canadian Journal of Health Technologies – A New Journal From CADTH

April 22, 2021
A message from Suzanne McGurn, President and CEO of CADTH On behalf of the team at CADTH, I’m proud and excited to announce that we have launched the Canadian Journal of Health Technologies, a new open-access journal serving the Canadian and global health technology assessment (HTA) community. You can find it online at canjhealthtechnol.ca and ...

CADTH Recommends Gene Therapy for Infants With Rare Genetic Disorder

March 26, 2021
Onasemnogene abeparvovec (Zolgensma) is the first gene therapy used to treat spinal muscular atrophy — a rare progressive and life-threatening condition that often begins in childhood and is caused by a genetic mutation. Conditions for reimbursement include a price reduction and clinical criteria for initiating treatment. Today, CADTH recom...